'Safeguards' slowing down access to breakthrough drugs in India

New drugs are not reaching low and middle income countries. A study shows many medicines take years to become accessible globally. India's regulatory system needs to mature for quicker access to breakthrough therapies. Stronger intellectual property protection and global standardisation are key. This will help reduce delays in drug availability for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zm562ih
via IFTTT

Telangana’s loss is Andhra’s gain as pharma companies expand in Kurnool

Sigachi Industries and Virupaksha Organics are relocating expansion projects to Andhra Pradesh. They will establish new manufacturing units in Kurnool district's Orvakal Industrial Park. This move follows Telangana's decision to abandon its Pharma City plan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HoI8ZSY
via IFTTT

Respiratory drug sales peak in November amid worsening AQI

India's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previous years. This trend highlights a strong link between pollution and illness. States like Uttar Pradesh and Uttarakhand saw significant sales increases for asthma and COPD treatments. Antihistamine use also climbed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xI32Cmw
via IFTTT

Dr Reddy’s inks licensing deal to sell Immutep’s cancer drug

Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute the Australian company's cancer therapy, eftilagimod alfa. This significant deal, valued at up to $350 million, grants Dr. Reddy's distribution rights across most global markets, excluding North America, Europe, Japan, and Greater China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnlBJLy
via IFTTT

ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar Shaw

Biocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves financial health. The combined entity will leverage synergies across manufacturing, R&D, and commercial operations. This integration aims to accelerate launches in major markets and unlock significant growth opportunities for the unified global player.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rvdhy2q
via IFTTT

Biocon to make Biocon Biologics a wholly owned subsidiary

Biocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Biocon will acquire remaining stakes through a share swap. The deal values Biocon Biologics at $5.5 billion. This integration aims to streamline operations and enhance strategic focus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CZqtSm5
via IFTTT

Abbott asks stockists to buy only from authorised suppliers

Spurious medicines were seized in Puducherry, prompting drug maker Abbott Healthcare to warn stockists. They must buy only from authorized suppliers. The government alerted the Drug Controller General of India about the circulation of fake drugs. The All India Organisation of Chemists and Druggists issued an advisory for safe business practices. This is a serious trade alert.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npGh9NW
via IFTTT

Lupin gets USFDA nod for multiple sclerosis drug

Drug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tentative approval from the USFDA for Siponimod Tablets. This new product will be manufactured at Lupin's Pithampur facility. Siponimod Tablets are bioequivalent to Mayzent tablets and treat relapsing forms of multiple sclerosis in adults.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fWTzvcA
via IFTTT

AI and technology tackling India’s growing stroke crisis: Early detection and prevention take centre stage

India faces a mounting crisis with a 51% rise in stroke cases over the last 30 years, recording 1.25 million new strokes in 2021 alone. Yet only a quarter of Indians have access to stroke-ready hospitals. Doctors at the Medtronic X EconomicTimes.com “Stroke Pe Rok” webinar agreed that creating awareness, improving primary care screening, and leveraging emerging technology must become urgent priorities to save lives and reduce stroke burden in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3K5o8sy
via IFTTT

GSK India plans big 'reinvention', MD Bhushan Akshikar reveals

GlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the next 4-5 years. This growth will be driven by a strategic shift towards specialty drugs in oncology and liver diseases. Adult vaccination is also a key focus area.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nvbyTH2
via IFTTT

NABL accreditation sets the stage for Lords Mark Microbiotech’s growth and preventive health push

Lords Mark Microbiotech, a Lords Mark Industries subsidiary, has earned NABL accreditation. This validates their diagnostic services. The company plans to open 200 labs and 2,000 collection centers nationwide in two years. They aim to become a top pathology player. An Organ Health Score offers personalized health insights. This expansion focuses on preventive healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1HWOlN9
via IFTTT

Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qikjFVD
via IFTTT

Sun Pharma unit to invest Rs 3,000 cr on new plant in Madhya Pradesh

Sun Pharmaceutical Industries' subsidiary, Sun Pharma Laboratories Ltd, has approved a Rs 3,000 crore investment for a new greenfield formulations manufacturing facility in Madhya Pradesh. This significant expansion by the Mumbai-based drug major aims to bolster its production capabilities. The announcement comes as Sun Pharma's shares saw a slight increase on Wednesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F76BokX
via IFTTT

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide

The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZcG9JDB
via IFTTT

Novo Nordisk India partners with Healthify to launch AI-enabled patient support programme

Novo Nordisk India and Healthify have launched a new programme. It offers AI-assisted lifestyle guidance for people with obesity. This partnership aims to improve patient experience and treatment results. An AI assistant will help users track nutrition throughout their treatment journey.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrLORbi
via IFTTT

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26

The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy's is restricted from selling the drug within India until March 2026. The court acknowledged a valid challenge to Novo Nordisk's patent for semaglutide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/upk0RgU
via IFTTT

Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs biz

Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9ITnu4N
via IFTTT

Cough syrup row puts regulators on overdrive to test pharma products

Indian drug companies are significantly increasing product testing. This surge follows strict government rules and joint inspections by regulators. The focus is on ensuring quality after recent contamination issues. Testing volumes have jumped dramatically. Companies are investing in specialized equipment to detect toxic substances. This heightened vigilance aims to safeguard public health and maintain the integrity of India's pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p2w1POC
via IFTTT

Wockhardt gets NDA status for novel antibiotic Zaynich

Wockhardt, an emerging powerhouse in the Indian pharmaceutical arena, has just scored a game-changing triumph! The US health regulator has given the green light to its New Drug Application for Zaynich, a cutting-edge antibiotic. This pivotal moment signifies the first occurrence of an Indian firm securing FDA acceptance for a New Chemical Entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYnqwyE
via IFTTT

Lupin gets USFDA nod for biosimilar drug

Lupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at Lupin’s Pune facility. Armlupeg aims to reduce infection risk from chemotherapy, and Lupin plans to expand its US biosimilar portfolio. The US market for Pegfilgrastim is worth over $1.29 billion annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Tj2Ivca
via IFTTT

Sun Pharma brings global psoriasis drug ILUMYA to Indian market

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This novel treatment, Tildrakizumab, has a proven track record globally for providing significant and sustained skin clearance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e5Ki80u
via IFTTT

Lupin Pharma, TPG Capital & EQT in talks to acquire Lalvani family-owned Vitabiotics

Indian drugmaker Lupin and private equity firms are exploring the acquisition of UK's Vitabiotics. The deal is valued at approximately one billion pounds. Several Indian companies had previously considered the acquisition but stepped back due to valuation concerns. Vitabiotics' Indian arm, Meyer Vitabiotics, contributes significantly to its annual sales. The nutraceutical market in India is experiencing rapid growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sNV1AuZ
via IFTTT

Torrent Pharma fined Rs 41 crore over alleged wrong GST refund

Torrent Pharmaceuticals has been fined Rs 41 crores by the Central GST Ahmedabad South Commissionerate. The company faces allegations of wrongful refund claims on export of goods. Torrent Pharmaceuticals plans to appeal the order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6HOgYLl
via IFTTT

Apollo Pharmacy targets 10 crore customer base in 5 years, to open 2 new stores per day: CEO

Apollo Pharmacy plans an aggressive expansion, aiming to open two new stores daily to reach a customer base of 10 crore within five years. Having surpassed 7,000 stores, the omni-channel network seeks to enhance its neighbourhood presence and ensure widespread access to quality medicines. The company also reported its loyalty program, Apollo Circle, has crossed 10 million members.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8JLC52k
via IFTTT

Generic HIV drug rollout to take a hit on trial push

India's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts warn this will delay access to the affordable generic version for millions in India and other low-income nations. Drug maker Hetero Labs sought the waiver to speed up the launch of the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BDUcR9e
via IFTTT

Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Glenmark Pharmaceuticals has received a positive report from the US health regulator. The company's manufacturing facility in Monroe, North Carolina, has been classified as Voluntary Action Indicated. This development means the facility can now restart commercial manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTzZfPs
via IFTTT

Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classification

Biocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classification means that while some objectionable conditions were found during the inspection, the agency is not pursuing regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mD6zjSv
via IFTTT

Kauvery Hospitals' promoters look to buy back 5% stake from Lightrock

Kauvery Hospitals' leadership is engaged in discussions to repurchase shares from the investor Lightrock, with the valuation of the healthcare chain set at ₹5,000 crore. Anticipating a public offering in the next two years, the group is poised to ramp up its bed capacity significantly. The primary goal for the promoters is to reclaim a stronger stake in their enterprise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RuNktyQ
via IFTTT

Lord’s Mark Industries acquires 85% stake in Renalyx to scale indigenous dialysis technology

Lord's Mark Industries has acquired an 85% stake in Renalyx Health Systems, a Bengaluru-based med-tech firm known for its AI-powered smart hemodialysis machine. This strategic move aims to bolster Lord's Mark's presence in advanced medical technologies, particularly for chronic kidney disease. Renalyx will spearhead R&D for kidney and liver devices, enhancing renal care accessibility across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jNZkagl
via IFTTT

China holds all the cards in global pharmaceuticals despite India’s bid to reshuffle the deck

China's dominance over raw materials for medicines presents a significant supply-chain vulnerability for the US. A US commission urges Congress to require pharmaceutical firms to report supply chain origins and encourage diversification away from China, highlighting the risks of over-reliance on a geopolitical rival.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K5BSoNt
via IFTTT

Sterling Biotech case: GoI to examine impact of Supreme Court judgment

The government is reviewing the Supreme Court's Sterling Biotech judgment, which dropped criminal charges against promoters in exchange for a ₹5,100 crore payment. While not a precedent, the ruling raises concerns for lenders and could impact similar fraud cases, potentially encouraging other offenders to seek settlements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InojfUu
via IFTTT

Baby Memorial Hospital front-runner for Star Hospitals, Fortis also in fray

Baby Memorial Hospital, backed by KKR, is reportedly the front-runner to acquire Star Hospitals for ₹2,500-2,700 crore. Fortis Healthcare is also in contention for the Hyderabad-based hospital group. Star Hospitals, promoted by cardiologist Gopichand Mannam, has two facilities in Hyderabad and annual revenues of ₹500-600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TMkXsQ6
via IFTTT

Glenmark launches fixed-dose triple therapy for COPD

Glenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three medicines to improve lung function and symptom control. It offers a new standard of care, especially for patients who find inhalers difficult. The therapy showed rapid improvement in lung function and breathlessness in a clinical study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UGXfCxT
via IFTTT

US FDA approves Novartis' gene therapy for rare muscle disorder

The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma offers a new option for a broader patient group. The therapy aims to replace a faulty gene crucial for muscle function.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WXvlp1M
via IFTTT

NPPA extends price cap on knee implants by a year

India's drug pricing regulator has extended the price cap on knee implants. This decision will continue to benefit patients by keeping costs down. The National Pharmaceutical Pricing Authority decided not to revise the prices for another year. Manufacturers had argued for a price increase, citing research and development needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HrkSoLW
via IFTTT

BlackRock exiting Rs 210 crore investment in People Tree Hospitals

People Tree Hospitals is facilitating an exit for BlackRock. BlackRock invested Rs 210 crore earlier this year. This investment aided the hospital chain's expansion and super-speciality services. It marked BlackRock's first major healthcare investment in India. People Tree Hospitals operates several branches across Bengaluru and Karnataka. Founder Jothi Neeraja stated commitment to honoring investor trust.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MsNBnAa
via IFTTT

Corner Office Conversation: Nandini Piramal of Piramal Pharma & Arjun Juneja of Mankind Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aojdn7U
via IFTTT

Biocon chief bats for dual-agency model to fast-track drug approvals

Biocon's Kiran Mazumdar-Shaw suggests a new drug approval system. The Indian Council of Medical Research would handle scientific reviews for new drugs and devices. The Central Drugs Standard Control Organisation would then grant final regulatory approval. This aims to speed up innovation and research in India's biotechnology sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bF3Gr5p
via IFTTT

Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4

Aurobindo Pharma's China facility is set to achieve break-even by the end of fiscal year 2026. The company anticipates significant growth driven by its Pen-G facility ramp-up and biosimilar portfolio commercialization. The US market will see contributions from the Dayton facility starting January. Aurobindo aims for a 20-21 percent margin target for FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HV0z9u1
via IFTTT

India mulls floating global tenders for key patented drugs amid supply gaps

The government is examining a proposal to float global tenders for more than 65 patented and proprietary medicines — including obesity, cancer, cardiac and diabetes drugs — to supply central healthcare institutions such as the armed forces’ medical wing and the Employees’ State Insurance Corporation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KxmGa58
via IFTTT

Pharma Industry warns minimum import prices plan could raise drug prices, hurt MSMEs

Pharma experts have flagged concerns over the government’s plan to set minimum import prices (MIP) for key drug ingredients such as Penicillin-G, 6APA and amoxicillin. They warn this will raise manufacturing costs, increase medicine prices and hurt over 10,000 MSMEs, potentially causing major job losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UrBJILh
via IFTTT

Government’s scheme to promote research and innovation evokes a massive response: Official

A month after the Department of Pharmaceutical (DoP) invited applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, an initiative to transform the sector into a globally competitive, innovation-driven sector, 700 applications have been received by the department so far.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ag4y0pc
via IFTTT

Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate growth in the biologics space. The company is uniquely positioned with interchangeable biosimilar insulins and aims to capitalize on the growing GLP-1 market, bolstered by its acquisition of Viatris' biosimilars business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtATbsf
via IFTTT

Quality issues: Regulator looks to tighten marketing & sale of drugs

India's drug regulator plans new rules for medicine marketers. Companies will need a license to sell and distribute drugs. This aims to improve drug quality and safety. The move will impact domestic and multinational firms. It is expected to help curb fake medicines. The regulator seeks to create a database of marketers for better oversight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/64tJVoU
via IFTTT

Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early momentum for Mounjaro in India, where the dual-action diabetes and obesity drug has clocked ₹450 crore in sales within seven months. He said India has a large unmet need, with nearly 100 million people living with obesity and diabetes, and that tirzepatide’s dual GIP and GLP-1 mechanism has set it apart in both weight and glucose management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vM7qKj1
via IFTTT

Ultra-processed foods displacing fresh meals worldwide, driving chronic disease burden: Lancet

Ultra-processed foods are increasingly displacing healthier options globally, contributing to chronic diseases. Researchers urge immediate public health action, emphasizing coordinated policies to curb UPF production, marketing, and consumption. This requires challenging corporate influence and advocating for sustainable food systems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wrFt7Tm
via IFTTT

Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya

Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring its successful insulin strategy. Ozempic is slated for launch within three months, with pricing to be determined by market research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZpOYeD7
via IFTTT

After cough syrup deaths, drug regulator moves to tighten rules on high-risk solvents; unlicensed village pharmacies also under scrutiny

India's drug regulator is taking action after children died from contaminated cough syrups. They are looking into how to check the quality of ingredients like propylene glycol. The regulator is also considering stopping unlicensed pharmacists from selling cough syrups in villages. Experts are being consulted on whether to replace propylene glycol in these medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6b8A5l3
via IFTTT

NCLT clears Sequent Scientific–Viyash Life Sciences merger worth ₹8,000 crore

Carlyle's portfolio companies, Sequent Scientific and Viyash Life Sciences, have received National Company Law Tribunal approval for their planned Rs 8,000 crore merger. This strategic combination aims to leverage back-end synergies between Sequent's animal health business and Viyash's human health drug manufacturing operations. Hari Babu Bodepudi, Viyash's founder, will lead the combined entity as CEO.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i0Y3AqC
via IFTTT

Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India

Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion, and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative therapies. They are working with partners to reach more people across India. This ensures their medicines benefit a wider population.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gjzOyd6
via IFTTT

Import price floor on cards for critical pharma inputs

India is setting a minimum import price for essential drug ingredients. This move aims to shield local manufacturers from cheap imports, particularly from China. The government is expanding this policy to include more raw materials. This initiative supports India's goal of becoming self-reliant in pharmaceutical production. The new rules will soon be announced.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LpjBwfM
via IFTTT

Deep Diamond India to enter preventive healthcare segment

The digital-health initiative, Deep Health India AI, is an intelligent, camera-based wellness platform that uses facial-scan technology to deliver real-time health insights, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IbtOxFS
via IFTTT

Pfizer launches new medication for migraine treatment

In a significant breakthrough for migraine sufferers in India, Pfizer has launched Rimegepant ODT, an innovative oral tablet that dissolves on the tongue. This medication provides rapid pain relief lasting up to 48 hours without the need for water, helping individuals reclaim lost days due to debilitating headaches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oPjyJ34
via IFTTT

AI tool in national disease surveillance helped issue over 5,000 alerts to health authorities: Data

Nearly 200 countries are legally bound by the International Health Regulations (IHR) to operate a national disease surveillance system. The IHR and World Health Organization work together in protecting global health security. News reports in print, electronic and online media are scanned by media scanning and verification tool under India's 'Integrated Disease Surveillance Programme' (IDSP) for unusual health events, which are then shared with authorities for further action, if deemed necessary.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwfPhjO
via IFTTT

Wealth Whisperers: Meet wealth psychologists who help the ultra-rich deal with money-related stress

Wealthy individuals, even after achieving financial success, often grapple with profound emotional turmoil like panic, insomnia, and identity loss. A new breed of professionals, wealth psychologists, are emerging to address the emotional meaning of money, helping the affluent navigate issues of guilt, isolation, and purpose beyond material gain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TF4NeJi
via IFTTT

Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors

India's pharmaceutical industry total market size is projected to reach $130 billion by 2030 and an impressive $450 billion by 2047, highlighting the country's growing role as a global pharmaceutical powerhouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/319b6s5
via IFTTT

Lupin launches generic injection in US with 180-day exclusivity

In an exciting development for mental health treatment, Lupin has introduced a generic version of a medication for schizophrenia and bipolar disorder in the US. This innovative product comes as an extended-release injectable suspension and is backed by a remarkable 180 days of exclusivity. This launch illustrates Lupin's commitment to advancing complex injectable solutions in a growing US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TxpG8tF
via IFTTT

Small pharma firms may face closure as regulator tightens quality checks

Many small drug makers face closure as regulators inspect facilities for quality standards. Thousands of plants may shut down if upgrades are not made. This could lead to drug shortages. Industry groups are seeking more time to comply. The government has set a deadline for these upgrades. Companies must submit plans for improvement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pv6ZORL
via IFTTT

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review

Biocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company is in advanced talks with minority investors for a share swap, considering various value creation options including an IPO or merger. This move aims to address acquisition-related debt and unlock shareholder value.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rdbjDKk
via IFTTT

Eli Lilly drops CVS drug plan for staff after Novo obesity deal: Report

Eli Lilly is switching its employee drug benefit plan from CVS Health to Rightway, a move reportedly linked to CVS's decision to stop covering Lilly's weight-loss drug Zepbound in favor of Novo Nordisk's Wegovy. Lilly stated the change was due to Rightway offering competitive fees and services aligned with employee interests.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8pKIOvw
via IFTTT

NTPC inks two pacts in Assam; to build burn ICU at KMCH, support TB patients

In a statement, the country's largest power producer said that it will construct a six-bed Intensive Care Unit (ICU) in the burn unit at Kokrajhar Medical College and Hospital (KMCH). The other project is nutritional support for 200 TB patients under the Pradhan Mantri TB Mukt Bharat Abhiyan in the district.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/173vOC2
via IFTTT

Lupin unit commissions oncology block at Vizag plant to expand CDMO biz

Drug firm Lupin has commissioned a new oncology block at its Vizag manufacturing plant. This dedicated unit will boost contract development and manufacturing services for high-potent active pharmaceutical ingredients. The facility supports clients throughout the oncology drug development lifecycle. It integrates process development and quality control labs for efficient operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TbUCeEN
via IFTTT

Emcure Pharma Q2 profit rises 25%, revenue up 13% on broad-based growth

Pune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supported by double-digit growth in both domestic and international markets. Net profit increased 24.7% YoY to ₹251 crore, while EBITDA rose 15.2% to ₹439 crore, with a margin of 19.3%, the company said on Tuesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uUoaJhO
via IFTTT

Novo, Emcure to launch weight-loss drug under new brand in India

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the company has not yet disclosed pricing details for Poviztra. Wegovy is currently priced between ₹17,345 and ₹26,050 across dosages in India. It is prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TrXuex9
via IFTTT

Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in India

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand access to the drug by leveraging Emcure's extensive distribution network and field force, addressing a significant need for wider reach beyond current accessibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bcV0lYA
via IFTTT

Novo Nordisk, Emcure to launch weight-loss drug under new brand in India

Novo Nordisk has partnered with Emcure Pharmaceuticals to bring Poviztra, their latest weight-loss medication, to the Indian market. This collaboration builds on Novo Nordisk's prior success with Wegovy and follows Eli Lilly's competition in this space. After the announcement, Emcure Pharma's stock experienced a notable uptick, signaling investor confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W6fIDRJ
via IFTTT

Cyber fraud: Dr Reddy's Laboratories loses Rs 2.16 cr after fraudsters hack email communication

Bengaluru police are investigating a Rs 2.16 crore cyber fraud where hackers infiltrated email communications between Group Pharmaceuticals and Dr Reddy's Laboratories. The fraudsters impersonated Group Pharmaceuticals officials, diverting the payment to a fraudulent account in Gujarat. The primary account has been frozen, and efforts are underway to recover the funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PhZ6Ufs
via IFTTT

Apollo’s Suneeta Reddy and Dr Preetha Reddy on the Next 10 Years of Healthcare

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HEXR6dn
via IFTTT

Centre asks states to take steps to encourage organ, tissue donation from road accident victims

In India, the challenge of organ shortages looms large. The government is calling on states to amplify efforts in organ donation. Vital steps include training first responders and enhancing hospital trauma centers for effective organ recovery. This initiative specifically targets increasing the number of organ donors from tragic road accident cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2uCrJ7Q
via IFTTT

Venus Remedies gets new market authorisations for drugs in Vietnam

Pharma major Venus Remedies has received new marketing authorisations in Vietnam for its drugs Methotrexate, Cefuroxime, and Irinotecan. These approvals expand the company's presence in South Asia's growing pharmaceutical market. This marks 29 active product approvals for Venus Remedies in Vietnam alone. The company is committed to increasing access to critical care therapies in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x7skF8H
via IFTTT

Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle

Metsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per share. Metsera's board recommended shareholders approve the deal. Pfizer aims to strengthen its position in the growing weight-loss drug market. The merger is expected to close soon after Metsera's shareholder meeting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ujIGeUB
via IFTTT

Drug regulator for strict compliance with new Schedule M

The state drug regulators have been asked to submit monthly reports to the Central Drugs Standard Control Organisation on the inspections and observations made and the action taken pursuant to such inspections. "This may be treated as top priority and compliance is required to be ensured strictly," the regulator said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfdV5a6
via IFTTT

Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drug

Alembic Pharmaceuticals has secured final approval from the USFDA for its generic Dasatinib tablets. These tablets are used to treat certain blood cancers in adults and children. The approval covers multiple strengths of the drug. Dasatinib is a vital medication for patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2v3le85
via IFTTT

Obesity drug Mounjaro becomes India's top-selling drug by value in October

Eli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps control blood sugar and slows digestion. Demand for such drugs is increasing in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MFQHWda
via IFTTT

'Opaque pricing cripples Ayushman drug coverage'

The Ayushman Bharat program successfully delivers hospital care, but it falters when tackling the high costs associated with medications for chronic and rare conditions. Patients frequently have to pay out of pocket for these essential drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUkz5Dv
via IFTTT

Apollo Hospitals eyes Q4 FY26 listing for HealthCo amid major restructuring

Apollo Hospitals plans to list its Apollo HealthCo arm by the fourth quarter of FY27, following a multi-layered restructuring. The hospital chain is also set to add approximately 3,650 operating beds over the next five years with an investment of Rs 8,300 crore, funded by internal accruals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aR9TDjW
via IFTTT

Bayer gets nod to market Kerendia for heart failure treatment

Bayer has secured approval in India for its therapy Kerendia to treat heart failure. This drug, finerenone, is already used for chronic kidney disease linked to type 2 diabetes. The expanded use targets heart failure types that have lacked effective treatments. Finerenone now addresses major health issues in India, including cardiovascular and kidney diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r75jNz8
via IFTTT

Sun Pharma’s US innovative drug sales surpass generics for the first time

Sun Pharma's U.S. innovative medicine sales have surpassed generics for the first time, driven by key products like Ilumya and Cequa. The launch of Leqselvi for alopecia has been well-received, with further growth anticipated from upcoming launches like Unloxcyt. This marks a significant shift in the company's revenue streams.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6reqMC
via IFTTT

Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences announced a significant development for beta-thalassemia patients. The US Food and Drug Administration has granted Orphan Drug Designation to Desidustat. This novel product aims to treat the rare blood disorder. The designation supports the development of medicines for diseases affecting fewer than 2 lakh people in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ixsU2Vp
via IFTTT

Sun Pharma's US innovative drug sales surpass generics for first time

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The company is evaluating its current footprint and considering localization options, though the tariff's impact on its product portfolio remains uncertain. Sun Pharma also confirmed upcoming launches and R&D investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7qIJbws
via IFTTT

Novelis says September fire at New York plant to hit FY26 cash flow up to $550-650 mn

Novelis anticipates a significant financial hit from a September fire at its New York plant. The company expects free cash flow to decrease by $550-650 million this financial year. Adjusted earnings before interest, tax, depreciation and amortisation will also be impacted. Restoration efforts are underway, with the Hot Mill expected to restart by end-December 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ios8Z9F
via IFTTT

Novelis expects cash flow impact of up to $650 mn from Oswego fire

Novelis anticipates a $550-$650 million negative impact on free cash flows this fiscal due to a September fire at its Oswego unit. The company expects to restart the hot mill in December, with insurance expected to cover 70-80% of property damage and business interruption losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iswVXtx
via IFTTT

Knee implant ceiling rates to be reviewed

Next week, the National Pharmaceutical Pricing Authority (NPPA) of India will delve into the pricing caps for knee implants, a move that previously helped slash costs for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OrTcBNL
via IFTTT

Glenmark to launch generic drug to treat metabolic acidosis in US

Glenmark Pharmaceuticals is set to launch an 8.4 per cent Sodium Bicarbonate Injection in the United States. This generic medication treats high acid levels in the body. The company expects to begin distribution this month. The drug is therapeutically equivalent to Abbott Laboratories' product. This move follows significant annual sales for the medication in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/niSgEa2
via IFTTT

Novo sharpens India focus with bigger bets on niche hospitals

Novo Holdings is boosting its investments in India. The company is looking at single-specialty hospitals and contract drugmakers. This move targets high-growth healthcare segments. Novo Holdings is already in talks with several Indian companies. Their investment size in India has grown significantly. They are focused on specialized healthcare and complex drug manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d7owOcB
via IFTTT

Cipla to fully acquire Inzpera Healthscience

Drug maker Cipla has acquired Inzpera Healthscience for approximately Rs 111 crore. This strategic move combines Inzpera's paediatric products with Cipla's distribution strength. The deal aims to boost growth and scalability in the pharmaceutical and wellness sector. Inzpera, founded in 2016, focuses on differentiated paediatric offerings. The acquisition marks a significant step for Cipla in expanding its market presence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsfdvb
via IFTTT

AIMS hospital founder looks to buy back PE investors' 49% stake

In a bold move to regain control, Narendra Pandey, the visionary behind the Asian Institute of Medical Sciences, is negotiating to repurchase a 49% share from private equity players. He aims to secure around ₹500 crore for this venture as the hospital’s current valuation hovers between ₹1,000-₹1,200 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJLiBpe
via IFTTT

AI helping doctors spend more time with patients, cut down on paperwork: Stanford Medicine’s Priya Singh

In an interview with The Economic Times, Priya Singh, Chief Strategy Officer and Senior Associate Dean at Stanford Medicine, talks about how Stanford is building the next generation of healthcare leaders through executive education and artificial intelligence. She explains that the programmes—targeted at senior and mid-level healthcare professionals—focus on leadership and innovation rather than serving as pathways to U.S. jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MCt83oO
via IFTTT

Narayana Health buys UK's Practice Plus Hospitals

Bengaluru's Narayana Health is making waves in the UK healthcare landscape with its acquisition of Practice Plus Group Hospitals, which manages 12 facilities. This strategic move is all about delivering affordable healthcare options to a broader audience.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uJTX7bp
via IFTTT

Narayana Health acquires UK’s Practice Plus Group Hospitals in Rs 2,200 crore deal

Narayana Hrudayalaya Ltd has acquired UK's Practice Plus Group Hospitals for approximately Rs 2,200 crore. This strategic move marks Narayana Health's entry into the UK healthcare market. The acquisition includes seven hospitals and several other facilities. Dr Devi Shetty stated the deal aims to make private healthcare more accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mZigRxT
via IFTTT

US biosimilar norms to keep local drug cos in good health

With the new regulations set by the US FDA, the pathway to creating biosimilars will be both faster and more cost-effective. This development is a game changer for Indian firms like Biocon and Dr Reddy's Laboratories, allowing them to provide more economical medicines to patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FT7B2hj
via IFTTT

Made in India new generation heart stent receives major global recognition

An Indian-made heart stent, Supraflex Cruz, has demonstrated a lower failure rate in high-risk patients compared to a US-made market leader. The TUXEDO-2 trial, conducted in India, showed the Indian stent to be non-inferior and resulted in significantly lower Target Lesion Failures, including cardiac death and heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aiTWQR7
via IFTTT

Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ cr

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growing chronic portfolio. The company maintained its second position in India's chronic market and saw significant progress in its U.S. respiratory and biosimilar segments, with four major respiratory assets slated for launch by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJO7TED
via IFTTT

Zero GST on health insurance plans sparks 38% surge in demand: Report

Health insurance demand has surged by 38 percent following the removal of GST. Individuals are now opting for higher coverage amounts, with the average sum insured increasing significantly. This trend is observed across various age groups and even in smaller cities. The exemption makes health and life insurance more affordable, encouraging comprehensive protection against rising healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PJdcy73
via IFTTT

Drug cos forging data for approval, mislabelling brands to be barred

In a bold move to combat deception in the pharmaceutical industry, the government is instituting strict penalties for drugmakers caught submitting forged or misleading documents during the approval process. This initiative is a direct response to the tragic incidents of child fatalities linked to tainted cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ltOwLk
via IFTTT

Govt aligns packaging rules for medical devices, eases compliance burden

Attention healthcare providers: New packaging regulations for medical devices have just come into effect! These amendments are designed to ensure that packaging aligns seamlessly with existing medical device standards. This simplification not only supports businesses by streamlining compliance but also enhances clarity for consumers making informed choices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Yko71jI
via IFTTT

Amway to invest $12 million in India to enhance physical presence

Amway plans a USD 12 million investment in India over the next three to five years. This will establish new stores nationwide, aiming to boost Amway's presence. The company also intends to increase exports from India. Amway sees India as a significant growth market with strong potential for its health and wellness products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TCHlwZn
via IFTTT

Indian pharma & healthcare sector saw $3.5 bn deals in Q3 2025: Grant Thornton Bharat

The Indian pharmaceutical and healthcare sector saw robust deal activity in Q3, with 72 transactions totaling USD 3.5 billion. This surge, driven by a sharp rebound in private deals and high-value acquisitions like Torrent Pharma's stake in JB Chemicals, reflects renewed investor confidence in the sector's growth potential and consolidation plays.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZAxQeoK
via IFTTT

Sanofi India appoints Deepak Arora as Managing Director

Sanofi India has appointed Deepak Arora as its new Managing Director. Arora will lead the company's strategic vision for India, aligning it with Sanofi's global strategy. He will focus on accelerating innovation and agility across the organization. Arora brings over 30 years of pharmaceutical and healthcare experience from various international markets. His appointment aims to enhance patient service throughout India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pb75vEl
via IFTTT

Dr Reddy’s gets nod to make generic semaglutide for weight loss

Dr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. The company plans to market the drug as soon as Novo Nordisk's patent expires early next year. This move aims to tap into a growing market for obesity and diabetes management. Dr Reddy's is preparing for a competitive launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E4PLRBv
via IFTTT

Lupin launches generic drug to treat urea cycle disorders in US

Drug firm Lupin has launched a generic medication in the US. This new drug treats urea cycle disorders. It is an authorized generic version of Ravicti oral liquid. The medication helps patients manage the disorder. This is for those who cannot be managed by diet alone. Lupin's shares saw a slight dip on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/StLxhry
via IFTTT

Time has never been better for Pharma breakthroughs than today: Bayer executive Stefan Oelrich

Bayer, the renowned pharmaceutical powerhouse from Germany, is implementing a tiered pricing strategy on a global scale to make medications more accessible. The CEO emphasizes the necessity of earning returns to justify research investments. As innovation ecosystems shift, particularly towards regions like China, Bayer is proactively adapting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/foMhiNY
via IFTTT

Eli Lilly allows Cipla to sell weight loss drug under new brand in India

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under the brand name Yurpeak. This drug helps manage diabetes and obesity. It is administered as a once-weekly injection. Yurpeak will be available in multiple dose strengths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IX3GM0D
via IFTTT

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest autoimmune treatment options. These biosimilars to Stelara have received official clearance on October 17, heralding a new era of affordable treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z9nY6Mk
via IFTTT

Trump eyes fresh tariff probe focused on foreign drug prices

President Trump is initiating a new investigation into drug prices, aiming to compel foreign nations to pay the same as Americans for their medicines. This probe, under Section 301 of the Trade Act, could lead to tariffs or other trade actions against countries with lower drug costs, potentially escalating global trade tensions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/diflSr2
via IFTTT

Regulator to digitally monitor supply chain of cough syrups

In a groundbreaking effort to enhance public health safety, India's drug regulatory authority has unveiled a digital tracking system for cough syrup supplies. This initiative comes in response to alarming cases of harmful cough syrups surfacing in the market. The revamped Online National Drugs Licensing System now requires pharmaceutical manufacturers of solvents to register and obtain licenses through this portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkDGzXA
via IFTTT

COVID-19 vaccines may help some cancer patients fight tumors

New research suggests COVID-19 mRNA vaccines could help cancer patients. Those with advanced lung or skin cancer who received Pfizer or Moderna shots lived longer while on immunotherapy. The mRNA technology appears to enhance the immune system's ability to fight tumors. This finding offers a potential new approach for cancer treatment, with further studies planned.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1ZvlNyb
via IFTTT

CCI clears Torrent Pharma's proposal to buy stake in JB Chemicals

India's competition regulator CCI has approved Torrent Pharmaceuticals' acquisition of a stake in JB Chemicals and Pharmaceuticals. This deal, valued at Rs 19,500 crore, will make Torrent Pharmaceuticals the second most valued pharma company in India. The approval comes with voluntary modifications offered by both companies. This significant development marks a major consolidation in the Indian pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pE0Q7tI
via IFTTT

Dr Reddy's Srikakulam unit classified as voluntary action indicated by USFDA

Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BPErcRQ
via IFTTT

Glenmark, Dr Reddy's recall products in US: USFDA

Indian drugmakers Glenmark and Dr Reddy's Laboratories are recalling products in the United States. Glenmark is recalling oral contraceptive medication due to failed impurities. Dr Reddy's Laboratories is recalling muscle relaxant medication due to out-of-specification results. These recalls are initiated by the US Food and Drug Administration. India has many USFDA-compliant plants outside the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BU49wPp
via IFTTT

India develops first indigenously discovered antibiotic "Nafithromycin" effective against resistant respiratory infections

India has proudly introduced Nafithromycin, its first homegrown antibiotic, tackling stubborn respiratory infections with groundbreaking efficacy. Coupled with a significant leap in gene therapy for Haemophilia, these innovations underscore India's commitment to self-sufficiency in the pharmaceutical arena. The country is now embracing a model that fosters collaboration with the private sector, setting the stage for international acclaim in biomedical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sxOXMFd
via IFTTT

Strides Founder raises Rs 1000 crore to refinance debt

Arun Kumar, founder of Strides Group and OneSource, has secured ₹1,000 crore by pledging shares. This move refinances existing loans, extending maturities and simplifying repayments. The transaction aims to consolidate smaller borrowings into larger, long-term facilities. It reflects a broader effort to clean up the promoter's balance sheet and shows a decline in pledged shares, indicating deleveraging.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eUxw2VP
via IFTTT

Prerna launches CANTEL™: A MicroRNA-based blood test for breast cancer screening

PrecisionRNA Biotech from Hyderabad has launched Cantel, a new microRNA blood test for breast cancer screening. This test offers a simple and accurate alternative to traditional methods. It aims to improve early detection rates in India. Cantel is designed for women aged 30 and above. The company is seeking investors for nationwide expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FuEgW63
via IFTTT

Indian firms explore localisation of pharma production in Russia

The Russian market is attracting growing interest from Indian pharmaceutical companies exploring opportunities to establish production facilities across various regions of the country. This was announced by Moscow Government Minister and Head of the Department for External Economic and International Relations, Sergey Cheremin, during the " Russia-India. Mutual Efficiency" forum.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/amfci7u
via IFTTT

US Senator raises alarm over poor-quality drug imports from India and China, seeks tougher FDA inspections

In a letter to FDA Commissioner Martin Makary, Banks said the agency must "do more to protect the US drug supply," warning that lax oversight could endanger American consumers. He pointed out that inspections of foreign drug plants have not yet returned to pre-pandemic levels, even as the number of manufacturers continues to grow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xEIYczF
via IFTTT

India to force drugmakers to upgrade plants after fatal cough syrup crisis

India has denied drugmakers more time to upgrade manufacturing facilities. This decision follows the deaths of at least 24 children from contaminated cough syrup. The government mandated World Health Organization standards after similar incidents abroad. Despite pleas from smaller firms, officials are firm on the deadline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jZH0vhU
via IFTTT

Alchem International moves Delhi HC against single-judge order on ‘Alchem’ trademark

Alchem International is challenging a court order that stops it from using its name. The order prevents Alchem from selling products with the name 'Alchem' due to similarity with Alkem Laboratories' trademark. A division bench is reviewing the case. The court previously found the names phonetically identical. Alkem has used its trademark since 1973. Alchem started using its mark later.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oKYmCbZ
via IFTTT

Heart blockages, tumors, fractures: Now, you can see what’s wrong inside your body in 3D at this Delhi govt hospital

Delhi-NCR's Vardhman Mahavir Medical College and Safdarjung Hospital has introduced a virtual clinical anatomy laboratory. Patients can now view detailed 3D models of their own bodies. This technology uses CT or MRI scans to create interactive visuals of organs, bones, and tissues. It helps patients understand their medical conditions and treatments better.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/imOeHXW
via IFTTT

Lords Mark Industries Ltd. secures US FDA Registration, reinforces India’s position in global healthcare manufacturing

Lords Mark Industries Ltd. has achieved a significant milestone with US FDA registration for its surgical consumables, orthopedic supports, and hygiene products. This recognition underscores the company's manufacturing excellence. It opens doors to international markets, boosting exports and India's global healthcare manufacturing standing. The approved portfolio covers a wide range of essential healthcare items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3zsQDLj
via IFTTT

Under the scanner, yet generic cough syrups hit shelves

Worry spreads regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol detected in some, resulting in heartbreaking instances of child mortality. This situation sheds light on the questionable efficacy of regulatory measures, as many small-scale producers evade scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kwLCu7p
via IFTTT

Centre plans new law for stricter quality checks and surveillance of drugs, medical devices, and cosmetics

India is creating a new law to improve drug quality and safety. This legislation will give more power to regulators for checking medicines, medical devices, and cosmetics. The aim is to prevent fake and substandard products. This move follows global concerns and recent incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aYiSLR4
via IFTTT

Centre to bring law for strict quality checks, surveillance of drugs and cosmetics

India is creating a new law to improve drug quality and safety. This legislation will give more power to regulators for testing and monitoring medicines, medical devices, and cosmetics. The aim is to ensure stricter compliance and accountability. This move follows global concerns and recent incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fglp7bm
via IFTTT

Cloudnine Hospitals leads race to acquire Apollo Cradle

Cloudnine Hospitals is stepping into a pivotal role in the maternity and pediatric care sphere, as it engages in advanced discussions to acquire Apollo Cradle and Children's Hospital at a valuation of around ₹1,500 crore. Having signed an exclusivity pact, Cloudnine has kicked off due diligence procedures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NId1qZM
via IFTTT

Roche moves SC against Natco’s launch of generic Risdiplam in India

F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7rRmOF1
via IFTTT

India accuses Balaji Amines of making pharma-grade chemical without a drug-making licence

Balaji Amines faces accusations from Indian authorities for producing pharma-grade propylene glycol without a necessary drug manufacturing license. This comes after some batches were found to be substandard. The company states it only manufactured technical and food-grade PG for non-pharma clients. Investigations are ongoing, and the company's stock has seen a decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jFZ4eQd
via IFTTT

Aurobindo Pharma promoters raise Rs 2k cr to fund realty, other asset buys

The transaction is split into two parts. The Rs 650 crore Series 1 comes with a 24-month tenor and a two-year put and call option, and Rs 1,450 crore, which will be Series 2 with a four-year tenor. Series 1 will carry a coupon of 11.75%, while Series 2 is likely to be priced at 15.5%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9qK7MPH
via IFTTT

WHO warns of contaminated India cough syrups linked to 17 child deaths

The World Health Organization has issued a health advisory regarding three contaminated cough syrups from India. Specific batches of COLDRIF, Respifresh TR, and ReLife are identified. These products pose severe health risks. India's Central Drugs Standard Control Organization reported that 17 children under five died after consuming these syrups. Authorities confirm no contaminated medicines were exported from India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3HltM0L
via IFTTT

Cough Syrup deaths: Sresan Pharmaceuticals' license cancelled, company shut down

Tamil Nadu has cancelled the manufacturing license of Sresan Pharmaceutical, maker of Coldrif cough syrup, after it was linked to at least 22 deaths in Madhya Pradesh due to toxic contaminants. The state ordered comprehensive inspections of all pharmaceutical units following the incident and the arrest of the company owner.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PO1INFa
via IFTTT

ED raids seven Chennai sites linked to Sreesan Pharma over Coldrif cough syrup deaths

The Enforcement Directorate (ED) conducted searches at seven locations in Chennai concerning the Coldrif cough syrup case. These raids, under the PMLA, are linked to Sreesan Pharma, the manufacturer of the banned syrup. The cough syrup has been linked to the deaths of approximately 22 children, primarily in Madhya Pradesh and Rajasthan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KQfagzI
via IFTTT

DRL, Zydus recall drugs in US over manufacturing issues: USFDA

Dr Reddy's Laboratories and Zydus Lifesciences are recalling products in the US due to manufacturing issues. Dr Reddy's is recalling muscle relaxant injections over stability testing failures, while Zydus Lifesciences is recalling antiviral medication for failing impurity specifications. Both recalls are classified as Class II by the USFDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u9rhU6i
via IFTTT

Survey finds 90% Indians willing to pay more for certified healthcare

A Ficci and EY-Parthenon report reveals that 83% of Indian patients desire accessible healthcare information, with nearly 90% willing to pay more for certified quality. Despite India's healthcare efficiency, a national framework for clear quality standards is needed to empower informed patient choices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SgXm82Z
via IFTTT

Breast cancer cases on rise; junk food, lack of exercise contributing factors: Doctors

Breast cancer is a growing concern in India, projected to reach two lakh cases annually by 2030. Experts highlight lifestyle factors like lack of exercise, obesity, and westernized diets as key contributors. Genetic predispositions also play a role, necessitating increased genetic testing and early screening for high-risk individuals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TrWEhVU
via IFTTT

Natco Pharma to acquire significant stake in S African firm Adcock Ingram

Indian pharmaceutical company Natco Pharma is set to acquire significant stakes in South Africa's Adcock Ingram, a 135-year-old firm, in a R4.2 billion deal. This acquisition will make Adcock Ingram a privately-held entity, co-owned by Natco and Bidvest, with Adcock Ingram delisting from the JSE post-completion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uCvon8O
via IFTTT

Max Healthcare plans over ₹5,000 crore expansion, eyes pan-India presence: MD Abhay Soi

Max Healthcare has surpassed ₹1 lakh crore in market capitalization, becoming India's most valued healthcare company. The company plans a significant capex of over ₹5,000 crore for expansion, aiming to increase bed capacity substantially and extend its reach into tier-2 and tier-3 cities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8rt5jeA
via IFTTT

Panacea Biotec bags Rs 127 crore order for oral polio vaccines

Panacea Biotec has secured a significant deal to supply bivalent oral polio vaccines valued at Rs 127.2 crore to the Central Medical Services Society. This crucial supply, confirmed via a Letter of Acceptance, will be delivered in multiple phases over 90 to 480 days, bolstering India's ongoing polio eradication efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oU9hItu
via IFTTT

Trump & Co said to have shelved generic drug tariffs, Indian pharma stocks get booster dose

The Trump White House has halted plans for tariffs on generic drug imports, a decision welcomed by Indian pharmaceutical companies that supply nearly half of US generic prescriptions. This move reassures millions of Americans relying on affordable imported medications for various health conditions, averting potential price hikes and shortages.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ae6w8Wk
via IFTTT

MP cough syrup deaths: Maharashtra FDA orders inspection of liquid oral formulations

Following the deaths of 20 children in Madhya Pradesh due to a contaminated cough syrup, the Maharashtra FDA has initiated a special drive. This includes inspecting manufacturers and testing liquid oral formulations from hospitals and distributors to ensure quality and prevent similar incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cJTtEmL
via IFTTT

Drug regulatory body steps up heat on state units amid cough syrup lapses

India's drug regulator has directed state authorities to enforce strict testing of all raw materials used in medicines. This action follows the tragic deaths of children due to contaminated cough syrups. Investigations revealed manufacturers were not testing excipients, leading to the use of industrial-grade materials unfit for human consumption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mwY1vCO
via IFTTT

Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launch

Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within six months of its March launch. The weight-loss and diabetes medication posted ₹80 crore in September sales, surpassing popular brands and attributed to its superior efficacy and first-mover advantage over competitors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VGHjYOt
via IFTTT

Sresan Pharma, maker of Coldrif, broke multiple rules: Officials

Sresan Pharma, the manufacturer of Coldrif cough syrup linked to at least 16 child deaths, allegedly ignored numerous quality standards. A central inspection revealed a "shoddy and neglected state" at their Tamil Nadu facility, with significant violations in raw material testing and batch release.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tYyUbXI
via IFTTT

The first 90 days: A doctor’s checklist for people newly diagnosed with type 2 diabetes

The first 90 days after a type 2 diabetes diagnosis are crucial for managing the condition and reducing heart disease risks. Experts emphasize understanding the body's response to high blood sugar, adopting healthy lifestyle foundations like smart eating and regular exercise, and seeking support to lay the groundwork for long-term health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2sLQ5r
via IFTTT

Eli Lilly to invest $1 billion in India, expand manufacturing and introduce oral weight-loss drug

Eli Lilly is significantly expanding its Indian operations with over $1 billion in contract manufacturing investments and plans for a global capability center. The US pharma giant is positioning India as a key hub, preparing to introduce an oral version of its experimental weight loss drug orforglipron and a new manufacturing hub in Hyderabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zgTGPxw
via IFTTT

"Classical example of legal illiteracy": IMA on arrest of doctor in child deaths from contaminated cough syrup

The Indian Medical Association has condemned the arrest of a pediatrician in Madhya Pradesh following child deaths from contaminated cough syrup, calling it "legal illiteracy" by police. The IMA demands action against actual culprits and compensation for affected families, emphasizing regulatory failures and the spurious nature of the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kPIKN2R
via IFTTT

Kerala bars all medicines for children under 12 without prescription

Kerala's Health Department mandated doctor prescriptions for all medicines given to children under 12, citing cough syrup concerns. An expert panel will study cough medicine use to formulate new guidelines. This follows reports of child deaths outside Kerala linked to toxic cough syrups, prompting awareness campaigns and suspension of problematic batches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrbwHzf
via IFTTT

Nanavati Max Hospital inks pact with Namangan Viloyat Republic Hospital in Uzbekistan

Mumbai's Nanavati Max Super Speciality Hospital has partnered with Uzbekistan's Namangan Viloyat Republic Hospital to enhance medical services. This collaboration facilitates knowledge exchange and clinician training in key specialties like multi-organ transplantation, while also providing advanced treatment for Uzbek patients in India. The agreement aims to establish transplant programs and streamline patient care pathways.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hz69rVK
via IFTTT

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers, increasing the availability of key drugs like Mounjaro. This strategic move leverages India's skilled workforce and includes a new Hyderabad facility to oversee contract manufacturing, despite global shifts towards US production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xzfFbtB
via IFTTT

Cough syrup issue: Health ministry directs rational use of medication

Union health secretary convened a meeting with states to address drug quality after multiple child deaths linked to contaminated cough syrups like Coldrif, found with DEG/EG. States were directed on rational use, while DGHS advised against prescribing such medicines for children under two, emphasizing careful evaluation for older kids. Probes are underway, and some states have banned the syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fpu3oe4
via IFTTT

NSE to build Rs 380-crore facility for cancer treatment at Tata Memorial Centre

NSE will build a 380 crore rupee cancer treatment facility at Tata Memorial Hospital. This 11-storey block and bone marrow transplant centre will be in Navi Mumbai. It will serve 1.3 lakh outpatients and conduct over 600 BMTs annually. The facility will have 60 beds. Operations are expected to begin by July 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E3MQqC6
via IFTTT

India's TB fight gets a boost: New Made-in-India diagnostic tests cut cost & time

India's ICMR has validated two new indigenous TB diagnostic tools from Huwel Lifesciences. The Quantiplus MTB FAST kit offers cheaper, open-system RT-PCR testing on existing machines, while UniAMP MTB uses non-invasive tongue swabs for patient-friendly diagnosis. These innovations promise faster, more accessible, and affordable TB detection, boosting India's elimination efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HYprjS0
via IFTTT

Torrent Pharma gets demand notices totalling Rs 6.63 cr from NPPA

Torrent Pharmaceuticals reported receiving demand notices from the NPPA. The notices total over Rs 6.63 crore. They allege overcharging for five drugs between January 2016 and November 2018. The company stated these notices were received on October 3, 2025. Torrent Pharmaceuticals expects no material financial impact from this development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrTJDqE
via IFTTT

Health Ministry confirms Diethylene Glycol beyond permissible limits in Coldrif cough syrup amid child deaths in Raj, MP

The Ministry of Health confirmed Coldrif Cough Syrup from Sresan Pharma's Kanchipuram unit contained diethylene glycol (DEG) above permissible limits, following investigations into child deaths in Madhya Pradesh and Rajasthan. Tamil Nadu banned its sale, halting production. Authorities initiated risk-based inspections and advised against prescribing cough syrup to children under two.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1aO7u2
via IFTTT

Tamil Nadu bans ''Coldrif'' cough syrup after child deaths in MP, Rajasthan

Tamil Nadu has banned the sale of 'Coldrif' cough syrup, manufactured by a city-based firm, following suspicions linking it to 11 child deaths in Madhya Pradesh and Rajasthan. Inspections were conducted, and samples are being tested for Diethylene Glycol. The Union Health Ministry also advised against prescribing cough and cold medications for children under two years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y2LmXx6
via IFTTT

Isabgol processors threaten to halt purchases from October 6 over GST

Isabgol processors threaten to halt purchases from farmers due to GST ambiguities, locking up capital for over a year. The industry, exporting ₹3,500 crore annually, faces financial stress and slowed exports as unclear classifications force them to pay GST on seeds, despite refunds. They demand government clarification.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/szVjFdB
via IFTTT

Indian Pharmaceutical Alliance appoints Zydus Lifesciences MD Sharvil Patel as new president

The Indian Pharmaceutical Alliance (IPA) has appointed Sharvil Patel of Zydus Lifesciences as its new President, with Glenn Saldanha of Glenmark as Vice President. This leadership transition occurs as the industry navigates GST reforms and strengthens its global position in specialty medicines. The new team aims to drive innovation, patient access, and quality healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/h4iGfDN
via IFTTT

IPA names Zydus Lifesciences MD Sharvil Patel as President

Sharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice president. The IPA represents 23 national pharmaceutical companies. The new team will build on reforms and breakthroughs. They will focus on innovation, patient access, and quality in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GYj4I3U
via IFTTT

Panacea Biotec gets supply order from UNICEF for oral polio vaccines worth Rs 315 cr

Panacea Biotec has received a long-term supply order from UNICEF. The order is for bivalent oral polio vaccines. It is valued at USD 35.65 million. Supplies will commence from April 2026 and continue until March 2030. This agreement covers vaccine requirements for UNICEF. The company will provide vaccines in 10 and 20 vial presentations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ra1qZi5
via IFTTT

Government invites proposals under PRIP scheme for industry, startup projects

The government has invited applications for its Rs 5,000 crore Pharma-MedTech innovation scheme, aiming to support around 300 projects in new medicines, biosimilars, and medical devices. Revised guidelines offer enhanced financial assistance for MSMEs and startups, including higher support for strategic priority areas. Applications opened on October 1 via a digital portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zx32rmn
via IFTTT

Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say

Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European Association for the Study of Obesity published in Nature Medicine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MtGbVzl
via IFTTT

Pricing depends on the country, Bayer looks at affordability: Executive

India has evolved significantly in the clinical trial setting...we have a significant number of patients and trials running in IndiaAshraf Al-Ouf Head, Pharmaceutical Commercial Ops, APAC, Bayer

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HNKCDW5
via IFTTT

'Contaminated' cough syrup linked deaths: NCDS collects water, entomological drug samples

NCDC collected water and entomological drug samples from Madhya Pradesh and Rajasthan after multiple children died of kidney failure, allegedly linked to contaminated cough syrup. These samples will be tested for infectious diseases, while state drug authorities await results from drug sample tests. Six children died in MP and one in Rajasthan, prompting a ban on 19 syrup batches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pf9E8HG
via IFTTT

Indian pharma Wockhardt seeks US approval for new drug to treat UTIs

Wockhardt has submitted a New Drug Application to the USFDA for its novel antibacterial agent, Zidebactam-Cefepime injection. This drug targets complicated urinary tract infections, including those caused by multidrug-resistant Gram-negative bacteria. This marks a significant milestone as the first USFDA NDA for a drug fully discovered and developed by an Indian pharmaceutical company, following successful global Phase III trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RVx0eK2
via IFTTT

Bayer seeks approval for key heart drug in India

Pharmaceutical major Bayer has filed for Indian approval of its patented drug finerenone (Kerendia) to treat heart failure patients with LVEF of 40 and above. This move aims to address India's growing early-onset heart disease burden. Already approved for chronic kidney disease, Bayer anticipates approval for this new indication by year-end, following successful trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dVobQRg
via IFTTT

Global report says 40% of clinicians in India could be using AI in work

Over 40 per cent of Indian clinicians are now using AI for work, a threefold increase from last year, surpassing global adoption rates. Despite this rapid embrace and optimism, challenges like clinician burnout and institutional gaps in AI training and governance remain. Experts urge focused action to translate digital health policies into effective practice.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lMGQCHV
via IFTTT

To what extent will Trump's tariffs impact Indian pharma? Govt assesses likely cost

Union Commerce ministry says US tariffs on pharma imports will not significantly impact India. India exports generic drugs, less affected by new rules. The nation is diversifying trade to counter US policy shifts. New free trade agreements with EFTA and the UK will boost marine exports. This strategy aims to broaden India's global market reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTi4Nu3
via IFTTT

Managing diabetes early: A smart choice to consider

Early management of type 2 diabetes is crucial in India, where the disease poses a significant health and financial burden. Starting treatment promptly and adopting lifestyle changes can reduce long-term complications like heart disease and kidney failure. Proactive conversations with healthcare providers and adherence to treatment plans are essential for better health outcomes and reduced healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FVeCJXm
via IFTTT

Lupin subsidiary inks pact to acquire Netherlands-based VISUfarma

Lupin's subsidiary will acquire VISUfarma BV for 190 million euros. This expands Lupin's European business and eye health product range. The acquisition strengthens Lupin's specialty franchise. It will enter the ophthalmology market. The deal is expected to close by late 2025. This transaction will enhance Lupin's growth and margin profile.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CniF2oE
via IFTTT

'Indian generics safe, tariffs unwise': Indian pharma association hits back after US tariff concerns

India's pharmaceutical industry, through the IPA, strongly countered US concerns regarding the quality of generic medicines, warning that tariffs would jeopardize America's drug security and increase reliance on China. The IPA cited FDA reports and independent testing affirming Indian facilities' high standards, highlighting billions saved for the US healthcare system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WNlVZxP
via IFTTT

Veterinary vaccine firms form association for collaboration with policymakers

India's leading veterinary vaccine manufacturers, including Hester Biosciences and Indian Immunologicals, have formed the Veterinary Vaccine India Manufacturers Association (VVIMA). This new association will serve as the industry's collective voice, aiming to collaborate with policymakers to foster innovation and position India as a global hub for animal vaccine research and production. Rajiv Gandhi leads as President.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q6S4p0g
via IFTTT

Glenmark, Granules, Zydus recall products in US over manufacturing issues: USFDA

Indian drugmakers Glenmark, Granules India, Sun Pharma, Zydus, and Unichem are recalling various products in the US market due to manufacturing issues. These include CGMP deviations, failed impurity specifications, and label mix-ups, leading to Class I, II, and III recalls initiated from late August to mid-September. The USFDA reported these voluntary actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qt7GKTg
via IFTTT

Highs & Lows: Could the microdosing of psychedelics be a key missing piece in the mental health jigsaw?

A Netflix documentary highlights the re-evaluation of mind-expanding substances like LSD, once banned but now experiencing a scientific renaissance. New research, including a study on pharmaceutical LSD for anxiety, suggests these psychedelics could redefine mental health treatment. However, overcoming public demonization and ensuring rigorous scientific trials are crucial for their widespread acceptance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lMRoBPA
via IFTTT

Just like bad medicine...Trump tariff pricks again; India not seen badly hit by US’ latest salvo

US President Trump’s 100% tariff on pharmaceutical products targets only branded and patented drugs, leaving India’s generic exports largely unaffected, experts say. The tariff, effective October 1, spooked pharma stocks but poses minimal immediate risk. India exported $9.8 billion in pharma to the US in FY25. Tariffs on furniture and trucks may benefit India, while bilateral trade talks continue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BroP82Q
via IFTTT

Weight-loss drug Ozempic to debut in India soon

Novo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive market against Eli Lilly's Mounjaro. Novo Nordisk's Wegovy also competes. The company's semaglutide patent expires next year, allowing generic versions. India has a large population with diabetes and obesity. Ozempic offers significant health benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZgRvDCk
via IFTTT

Diabesity: It’s more than you think

The intertwined rise of obesity and type 2 diabetes, termed 'diabesity,' presents a significant health challenge in India. This condition, driven by complex factors beyond lifestyle, faces stigma hindering effective treatment. Indians, despite appearing thin, often have higher body fat, increasing their risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ezLwAQI
via IFTTT

Trump delivers another bitter tariff pill. Who’s set to bite the dust?

A new tariff announced by President Trump will impose a 100% levy on patented pharmaceuticals entering the U.S. from October 1, 2025, unless companies have manufacturing facilities in the country. This policy raises uncertainties about which drugs will be affected and challenges the Indian pharmaceutical sector, which significantly contributes to the U.S. market—supplying 47% of generics and saving the U.S. healthcare system $219 billion in 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vjyk36t
via IFTTT

Trump's 100% tariff on pharma will not impact generic makers, says Indian Pharma Alliance

The Indian Pharmaceutical Alliance clarifies that Trump's proposed 100% tariff targets patented and branded drugs, not generics, potentially impacting a segment of Indian exports. While the immediate effect on Indian exports may be limited due to their focus on generics and existing US manufacturing presence, the industry is advised to prepare for future policy changes and explore advanced pharmaceutical opportunities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ctv2JXp
via IFTTT

Meril’s Mizzo Endo 4000 sets a new benchmark in robotic surgery

Meril, an Indian medical device company, has launched the Mizzo Endo 4000, a next-generation surgical robotic system. This advancement aims to enhance surgical precision and accessibility across various specialties. The system features AI-powered 3D mapping, an open console, and 5G-enabled telesurgery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bj4wYEX
via IFTTT

Alembic Pharma gets USFDA nod for generic drug to treat depression, anxiety

Alembic Pharmaceuticals Ltd. announced it has secured final approval from the USFDA for its generic Paroxetine extended-release tablets, available in 25 mg and 37.5 mg strengths. These tablets are therapeutically equivalent to Apotex Inc's Paxil CR and indicated for treating major depressive disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hfOoZ9A
via IFTTT

HIV-prevention drug to cost $40 a year from 2027

The two organizations have signed separate agreements with Indian pharmaceutical companies to produce cheaper generics of lenacapavir - a twice-yearly injection shown to reduce the risk of HIV transmission by more than 99.9% - for low- and middle-income countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RF2o8l5
via IFTTT

HCA Healthcare to invest $75 mln to set up Global Capability Center (GCC) in Hyderabad

HCA Healthcare inaugurated its Global Capability Center in Hyderabad, investing USD 75 million by 2025. The center, spanning 400,000 square feet, will employ 3,000 professionals by 2026, focusing on IT, supply chain, and finance. This strategic hub aims to drive innovation and operational excellence, supporting HCA Healthcare's patient care in the US and UK.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qXJHxSn
via IFTTT

Tata 1mg likely to get $200 mn booster shot; Novo, CPPIB, Permira and ChrysCap line up

Novo Holdings, CPPIB, Permira, and ChrysCapital have shown interest in investing in Tata Group’s online pharmacy 1mg, which seeks up to $200 million for its next growth phase. The investors, however, consider the $1.25 billion 2022 valuation too high, proposing $750–800 million instead. Some also want board seats, which Tata is unwilling to offer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtG0F8J
via IFTTT

India’s liver-heart-diabetes triangle: Why acting early could save your life

In India's bustling cities like Mumbai, a concerning trend emerges as fatty liver disease, now termed MASLD, quietly rises alongside diabetes and heart disease. Sedentary lifestyles, poor diets, and lack of awareness contribute to its prevalence, even among those with normal weight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vZsWTFx
via IFTTT

Vidal Health and Serum Institute collaborate on HPV vaccine access

Vidal Health, in partnership with Serum Institute of India, will launch a digital platform on October 1, 2025, to streamline HPV vaccine access and promote cervical cancer prevention. The platform offers convenient appointment booking, digital consent, and certification, ensuring a cashless and paperless experience. This collaboration aims to improve vaccine delivery efficiency and awareness, supporting national healthcare efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X5jEeYA
via IFTTT

India’s cheap birth control pills in US could vanish under Trump’s 250% tariff threat

Donald Trump's tariff threat jeopardizes affordable Indian medicines in the US. Birth control pills, hypertension, and depression treatments are most vulnerable. India, the world's pharmacy, faces potential export losses. Analysts foresee price hikes and supply chain disruptions. Indian firms may struggle to absorb tariffs. The US aims to boost domestic drug production. This move risks higher drug prices for Americans.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GdbjFB0
via IFTTT

India’s unique diabetes profile: The Indian diabetes phenotype—why our bodies react differently

Diabetes is rapidly increasing in India, affecting over 101 million people, often manifesting differently than in the West. Indians tend to develop diabetes earlier, even at lower weights, due to a "thin-fat" body type and less muscle mass. Genetic predispositions, poor early-life nutrition, and sedentary lifestyles contribute to this alarming trend, with many unaware of their condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cF9BOZp
via IFTTT

Drug companies flag concerns over timeline for carrying out regulator's manufacturing rule

Small and medium pharmaceutical companies are appealing to the health minister, raising concerns about stringent manufacturing standards imposed by the central drug regulatory body. These associations fear that the abrupt implementation timeline will force many MSMEs to shut down due to financial constraints and inability to meet the new requirements, potentially leading to medicine shortages.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Er6lSsU
via IFTTT

PE fund KKR closes third buy in Kerala, at Meitra Hospital

KKR, buoyed by its successful Max Healthcare exit, is expanding its hospital investments in South India. Its Kerala-based Baby Memorial Hospital (BMH) has acquired a majority stake in Meitra Hospital for ₹1,000-1,200 crore and is considering acquiring Star Care Hospital.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wRNYXId
via IFTTT

Rehabilitation: India's 'missing link' in healthcare

Experts at the IAPMR Mid-Term CME 2025 highlighted India's rehabilitation shortage, emphasizing that discharge is not the end of treatment. The lack of structured rehabilitation, inadequate insurance coverage, and the removal of PMR from the medical curriculum are contributing to delayed recovery and frequent readmissions. They advocate for mandatory rehabilitation protocols and increased awareness to improve patient outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/N0Gu4Fn
via IFTTT

India push into global natural healthcare market, government research institutions develop new drugs

India's herbal healthcare sector is preparing for a new growth phase, as traditional medicine blends with modern science to produce validated, affordable, and globally competitive solutions. This momentum was on full display at the recently concluded two-day CSIR Startup Conclave, where research institutions, startups, and policymakers joined forces to demonstrate how herbal formulations are moving from laboratories to the marketplace.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3sZLo72
via IFTTT

"Transformative shift in India's healthcare": Pharma alliance lauds GST reforms ahead of implementation

The Indian Pharmaceutical Alliance lauds the upcoming GST reforms, effective Monday, as a transformative step towards affordable healthcare. Prime Minister Modi's initiative reduces GST on most medicines from 12% to 5%, with complete exemption for 36 critical life-saving drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JgbqhIT
via IFTTT

Healthcare set to be more affordable as new GST rate kicks in from Sep 22: Pharma industry

From September 22, medicines and medical devices in India will become cheaper under new GST rates, making healthcare more affordable, say industry experts. Most drugs’ GST drops from 12% to 5%, while 36 critical life-saving medicines are fully exempt. Tax slabs on insurance, glucometers, and spectacles are also rationalised, easing costs for patients and improving access to essential care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dsCrcVk
via IFTTT

Fermenta board approves sale of environmental solutions biz to subsidiary

Fermenta Biotech on Friday said its board has approved transferring its environmental solutions business to a wholly owned subsidiary on a slump sale basis, effective October 1, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gJwf19o
via IFTTT

Fire at subsidiary unit temporarily hits production: Aurobindo Pharma

Aurobindo Pharma reported a fire incident on September 18, 2025, at its APL Healthcare Unit-IV in Andhra Pradesh due to a short circuit, causing temporary production disruption. The fire, contained with no casualties, impacted two out of nineteen lines, resulting in an estimated 3% reduction in monthly capacity. Refurbishment is underway, with operations expected to resume in a few weeks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aZvj2Ar
via IFTTT

PMO acts on pharma MSMEs 'crisis call'

The PMO has been alerted to potential medicine shortages and price increases due to stringent regulatory actions on pharmaceutical quality. The Federation of Pharma Entrepreneurs warns that many MSMEs face closure due to costly GMP upgrades, potentially impacting the supply of essential medicines and causing significant job losses. They are urging the government to extend the compliance deadline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gWrq3Yc
via IFTTT

Indian pharma sector to log 7-9% growth in FY26 despite US headwinds: ICRA

India's pharmaceutical industry is set to record healthy revenue growth of 7-9 per cent in FY26, even as challenges in the United States market continue to weigh on performance, noted rating agency ICRA in its latest sector outlook.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7iWKYxw
via IFTTT

Natco Pharma's Kothur unit classified as 'voluntary action indicated' by US regulator

Natco Pharma Ltd announced that its Kothur unit in Hyderabad received an Establishment Inspection Report (EIR) from the US FDA, classifying the facility as 'Voluntary Action Indicated' (VAI). The US FDA had previously conducted an inspection of the company's pharma division at the Kothur location. While objectionable conditions were noted, the agency does not plan immediate regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8N9RW41
via IFTTT

India ranks among top contributors in reporting adverse events: Drugs Controller General of India

DCGI Dr. Rajeev Raghuvanshi highlighted India's leading role in global adverse event reporting during the 5th National Pharmacovigilance Week. The week-long campaign, themed 'Your Safety, Just a Click Away: Report to PvPI', aims to encourage ADR reporting through simplified digital platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3KpDS7x
via IFTTT

AstraZeneca's asthma drug fails 'smoker's lung' study

AstraZeneca's Fasenra failed to reduce flare-ups in COPD patients in a late-stage trial, a setback for the company's efforts to address the severe lung disease. Despite this, AstraZeneca will analyze the data to understand the results better, while its rare disease drug Saphnelo succeeded in a lupus trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5ZxtNuS
via IFTTT

'Nimesulide' may come with warning label

Indian drug regulators have mandated cautionary labels for nimesulide, restricting its use as a second-line treatment for patients 12 years and older after exhausting first-line options. The labels must warn against use during pregnancy, lactation, or by women planning pregnancy, as well as in patients with renal or hepatic impairment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jh9fwUT
via IFTTT

Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions

Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to treat conditions like knee osteoarthritis and sleep apnea. Clinical trials are planned to investigate the impact of CagriSema and amycretin on various obesity-related comorbidities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/js6zR2W
via IFTTT

Scheme to promote innovation in pharma, medtech sectors to be launched this month: Pharma Secretary

The government will soon launch a scheme to boost innovation in the pharmaceutical and medical technology sectors. The PRIP scheme has a financial outlay of Rs 5,000 crore. It will support research and development. The scheme aims to reduce reliance on imports. Three medical device parks are expected to be functional by early 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hQu1WPy
via IFTTT